Small-molecule inhibitors binding to protein kinase. Part II: the novel pharmacophore approach of type II and type III inhibition
- 1 December 2008
- journal article
- Published by Informa Healthcare in Expert Opinion on Drug Discovery
- Vol. 3 (12) , 1427-1449
- https://doi.org/10.1517/17460440802580106
Abstract
Protein kinases are essential enzymes propagating cellular signal transduction processes and consequently emerged as central targets for drug discovery against a wide range of diseases with a strong historical focus on oncological disorders. Several high-resolution crystal structures of various ATP-competitive inhibitors in complex with their target protein kinases have been determined and represent a wealth of detailed information about binding modes, inhibition mechanisms, and associated structure- activity relationships of target-bound small molecules. In this second part of a two-part review, we discuss the binding mode of inhibitors that target protein kinases in their inactive state. The scope of this review covers inhibitors for which crystal structures in complex with their respective kinases in the inactive state are available. Structural parameters of both inhibitors and kinases contribute to the complexity of designing kinase inhibitors. Kinase inhibitors that target the inactive state of a kinase have become a novel rule in the design of highly active and selective compounds. The combination of high-resolution structures of ligand-enzyme complexes with especially detailed kinetic studies will in the long-term help to develop new low-molecular weight type II inhibitors.Keywords
This publication has 65 references indexed in Scilit:
- A Src-Like Inactive Conformation in the Abl Tyrosine Kinase DomainPLoS Biology, 2006
- Sensing extracellular matrix: An update on discoidin domain receptor functionCellular Signalling, 2006
- Structural Basis for the Autoinhibition and STI-571 Inhibition of c-Kit Tyrosine KinaseJournal of Biological Chemistry, 2004
- p53 induction and activation of DDR1 kinase counteract p53-mediated apoptosis and influence p53 regulation through a positive feedback loopThe EMBO Journal, 2003
- Glivec (STI571, imatinib), a rationally developed, targeted anticancer drugNature Reviews Drug Discovery, 2002
- Pyrazole Urea-Based Inhibitors of p38 MAP Kinase: From Lead Compound to Clinical CandidateJournal of Medicinal Chemistry, 2002
- STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implicationsOncogene, 2001
- Structural Mechanism for STI-571 Inhibition of Abelson Tyrosine KinaseScience, 2000
- Potent and selective inhibitors of the Abl-kinase: phenylamino-pyrimidine (PAP) derivativesBioorganic & Medicinal Chemistry Letters, 1997
- Crystal structure of the tyrosine kinase domain of the human insulin receptorNature, 1994